Company profile

BIAL - Portela

Privately-held (family-owned) pharmaceutical company

Privately held: no public share price · Portugal

Assets

(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Eslicarbazepine acetate(Aptiom)
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Opicapone(Ongentys)
Approved
COMTSmall molecule
Parkinson's Disease
ZamicastatNo recent activity
Phase 3
DBHSmall molecule
Hypertension

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.